Science and Technology Daily, Beijing, August 5 (Reporter Qu Jian) According to the latest news from Sinopharm Sinopharm, the new crown inactivated vaccine production workshop of the Beijing Institute of Biological Products has passed the joint biosafety inspection organized by relevant national departments and is qualified for use. Previously, the workshop had obtained a new crown vaccine production license.
According to Sinopharm Sino Biotech, in the fight against the new crown epidemic, it has made a full attack on the three fronts of diagnosis, treatment, and prevention. It has achieved rapid and portable nucleic acid detection kits, plasma treatment methods for recovered patients, new crown-specific immunoglobulin and The new crown inactivated vaccine is a series of major innovations that lead the world. While fully advancing the research and development of vaccines, Sinopharm China Biological does not rely on it, taking the initiative to play its role as the main body of the enterprise, and constructing high-level biosafety production facilities in two biological products research institutes in Beijing and Wuhan.
The high-level biosafety production facility in Beijing that has just passed the inspection is currently the world's first and largest inactivated COVID-19 vaccine production workshop. During the whole process of design, construction and use of the workshop, Sinopharm Group and Sino Biotech followed the relevant national and World Health Organization biosafety norms and standards, introduced domestic and foreign experienced design teams, learned from international advanced experience, and followed the biosafety level 3 Protection standards for construction, management and maintenance. With the strong support of the Beijing Municipal Government, the Beijing Institute of Biological Products completed the construction of the workshop on April 15 in only 2 months, creating the "Vulcan Mountain" speed for the construction of the new crown inactivated vaccine workshop. In mid-July, relevant national departments organized experts to conduct a comprehensive inspection of the biosafety of the new crown vaccine production workshop of the Beijing Institute of Biological Products. They believed that the production workshop basically met the requirements of the relevant national standards and could be put into mass production of the new crown vaccine.
The high-level biosafety facility and supporting laboratory complex of the Wuhan Institute of Biological Products of China National Biotechnology Co., Ltd. was completed on July 1 and reached the conditions for delivery by the end of July. It strives to obtain relevant inspections and have production conditions as soon as possible. Wuhan Institute of Biological Products will also become the world's only biological product R&D and production unit with a high-level biosafety R&D laboratory and production facility complex. After the production workshops of the two research institutes are put into use, China Bio will be able to guarantee that the annual production capacity of the new crown vaccine will reach 220 million doses.